Key Equity Analysts at Robert W. Baird Kept their ‘”Hold”’ rating for Biogen Inc (NASDAQ:BIIB) Shares Today. Their Target Price per Share is Set to $290.0

January 21, 2018 - By Clifton Ray

 Key Equity Analysts at Robert W. Baird Kept their ‘

Investors sentiment increased to 1.13 in Q3 2017. Its up 0.25, from 0.88 in 2017Q2. It improved, as 59 investors sold Biogen Inc. shares while 283 reduced holdings. 96 funds opened positions while 292 raised stakes. 181.16 million shares or 0.28% more from 180.66 million shares in 2017Q2 were reported.

1,707 were accumulated by Cypress Asset Mgmt Inc Tx. Dowling & Yahnke Limited Liability Com holds 0.23% of its portfolio in Biogen Inc. (NASDAQ:BIIB) for 7,182 shares. Moneta Group Investment Advsrs Ltd Liability Company reported 703 shares. Sands Mgmt Ltd Liability reported 1.21 million shares. Lpl Fincl Ltd Limited Liability Company owns 45,381 shares for 0.05% of their portfolio. 259,829 were accumulated by Rockefeller Financial Inc. Naples Global Advsr Ltd Co reported 0.13% in Biogen Inc. (NASDAQ:BIIB). Renaissance Tech Lc invested in 120,161 shares or 0.04% of the stock. The New York-based Alliancebernstein Lp has invested 0.63% in Biogen Inc. (NASDAQ:BIIB). Quantitative Investment Mgmt Ltd stated it has 145,500 shares or 0.52% of all its holdings. Meiji Yasuda Life Ins holds 0.29% of its portfolio in Biogen Inc. (NASDAQ:BIIB) for 6,366 shares. California Public Employees Retirement accumulated 0.23% or 503,518 shares. Sun Life Financial invested in 0.09% or 3,063 shares. Contravisory Inv Management has 21 shares for 0% of their portfolio. Tokio Marine Asset Co Ltd stated it has 0.41% in Biogen Inc. (NASDAQ:BIIB).

Since January 9, 2018, it had 0 insider buys, and 1 insider sale for $1.92 million activity.

Biogen Inc (NASDAQ:BIIB) Rating Reaffirmed

The financial firm has just set a TP of $290.0 on Biogen Inc (NASDAQ:BIIB) shares. This is -15.31 % from the previous stock close. In an analyst note shared with investors on 30 October, Robert W. Baird reaffirmed their “Hold” rating on shares of BIIB.

Investors sentiment increased to 1.13 in Q3 2017. Its up 0.25, from 0.88 in 2017Q2. It improved, as 59 investors sold Biogen Inc. shares while 283 reduced holdings. 96 funds opened positions while 292 raised stakes. 181.16 million shares or 0.28% more from 180.66 million shares in 2017Q2 were reported.

1,707 were accumulated by Cypress Asset Mgmt Inc Tx. Dowling & Yahnke Limited Liability Com holds 0.23% of its portfolio in Biogen Inc. (NASDAQ:BIIB) for 7,182 shares. Moneta Group Investment Advsrs Ltd Liability Company reported 703 shares. Sands Mgmt Ltd Liability reported 1.21 million shares. Lpl Fincl Ltd Limited Liability Company owns 45,381 shares for 0.05% of their portfolio. 259,829 were accumulated by Rockefeller Financial Inc. Naples Global Advsr Ltd Co reported 0.13% in Biogen Inc. (NASDAQ:BIIB). Renaissance Tech Lc invested in 120,161 shares or 0.04% of the stock. The New York-based Alliancebernstein Lp has invested 0.63% in Biogen Inc. (NASDAQ:BIIB). Quantitative Investment Mgmt Ltd stated it has 145,500 shares or 0.52% of all its holdings. Meiji Yasuda Life Ins holds 0.29% of its portfolio in Biogen Inc. (NASDAQ:BIIB) for 6,366 shares. California Public Employees Retirement accumulated 0.23% or 503,518 shares. Sun Life Financial invested in 0.09% or 3,063 shares. Contravisory Inv Management has 21 shares for 0% of their portfolio. Tokio Marine Asset Co Ltd stated it has 0.41% in Biogen Inc. (NASDAQ:BIIB).

Since January 9, 2018, it had 0 insider buys, and 1 insider sale for $1.92 million activity.

Biogen Inc. (NASDAQ:BIIB) Ratings Coverage

Among 31 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 22 have Buy rating, 0 Sell and 9 Hold. Therefore 71% are positive. Biogen Idec Inc. has $450 highest and $268 lowest target. $353.21’s average target is 3.15% above currents $342.41 stock price. Biogen Idec Inc. had 97 analyst reports since July 23, 2015 according to SRatingsIntel. Morgan Stanley downgraded the shares of BIIB in report on Thursday, March 16 to “Equal-Weight” rating. The rating was maintained by Piper Jaffray on Thursday, January 18 with “Buy”. Jefferies reinitiated Biogen Inc. (NASDAQ:BIIB) rating on Tuesday, July 11. Jefferies has “Hold” rating and $310 target. The rating was initiated by Standpoint Research on Thursday, January 7 with “Buy”. Piper Jaffray upgraded the stock to “Overweight” rating in Thursday, November 5 report. BMO Capital Markets maintained the stock with “Outperform” rating in Monday, November 6 report. As per Wednesday, August 17, the company rating was maintained by Morgan Stanley. Cantor Fitzgerald maintained it with “Hold” rating and $27700 target in Tuesday, July 25 report. The stock of Biogen Inc. (NASDAQ:BIIB) has “Buy” rating given on Tuesday, October 17 by Mizuho. RBC Capital Markets maintained the stock with “Hold” rating in Wednesday, October 25 report.

The stock decreased 0.59% or $2.03 during the last trading session, reaching $342.41. About 1.23 million shares traded or 0.25% up from the average. Biogen Inc. (NASDAQ:BIIB) has risen 4.94% since January 21, 2017 and is uptrending. It has underperformed by 11.76% the S&P500.

Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on January, 25. They expect $5.52 EPS, up 9.52 % or $0.48 from last year’s $5.04 per share. BIIB’s profit will be $1.17 billion for 15.51 P/E if the $5.52 EPS becomes a reality. After $6.31 actual EPS reported by Biogen Inc. for the previous quarter, Wall Street now forecasts -12.52 % negative EPS growth.

Biogen Inc., a biopharmaceutical company, discovers, develops, makes, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company has market cap of $72.41 billion. The firm offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis ; FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It has a 21.04 P/E ratio. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies.

More news for Biogen Inc. (NASDAQ:BIIB) were recently published by: Marketwatch.com, which released: “Acorda shares jump 20% premarket on talk of possible takeover by Biogen, other …” on January 19, 2018. Fool.com‘s article titled: “Will 2018 Be Biogen Inc.’s Best Year Yet?” and published on January 14, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: